PDF-Future Technologies Conference FTC 2017 2930 November 2017 Vancouv

AsKOe KLtesLdeDepartment of Computer ScLence UnLversLt of CoOorado CoOorado SprLnJs amZKLtesLde1aKoocom SudKansKu umar SemZaODepartment of Computer ScLence UnLversLt of CoOorado CoOorado. C Canada August 16 2004 Paper No 1681 SEISMIC PERFORMANCE OF B UCKLING RESTRAINED BRACED FRAME SYSTEMS Stephen MAHIN Patxi URIZ Ian AIKEN Caroline FIELD and Eric KO SUMMARY A growing number of buildings in the US are using bucklingrestrained brace C Canada August 16 2004 Paper No 1628 EFFECT OF CONFINING SOIL PRESSURE ON RESPONSE BEHAVIOR OF RC PILES UNDER GROUND Takeshi MAKI and Hiroshi MUTSUYOSHI SUMMARY The objective of this paper is to clarify the ductile behavior of reinforced concrete pi C Canada August 16 2004 Paper No 4 MECHANICAL BEHAVIOR OF REINFORCED CONCRETE BEAMCOLUMN ASSEMBLAGE S WITH ECCENTRICITY Tomohiko KAMIMURA Hiroyasu TAKIMOTO and Shinya TANAKA SUMMARY Experimental work was carried out to study the mechanical behavior Revising& November November November November PI/PDsrole November November November Novemberstatement Jules Polonetsky. Co-Chairman and Director, Future of Privacy Forum. The Future of Privacy Forum (FPF) is a Washington, DC based think tank that seeks to advance responsible data practices. The forum is led by Internet privacy experts Jules Polonetsky and Christopher Wolf and includes an advisory board comprised of leading figures from industry, academia, law and a. STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (mITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -12%, 85% power. If non-inferiority and lower margin > 0, assessment for superiority. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 3rd Quarter. October-December 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. Estudio GS-US-311-1089 . Estudio GS-US-366-1216 . Estudio GS-US-366-1160 . . Diseño. Endpoints. Primario: proporción de pacientes . con C. V . < 50 c/mL a S48 (ITT, . snapshot. ) ; no inferioridad si el margen inferior de IC95% de dos colas para la diferencia = - 8%, poder 85%. Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials Andrew Hill, Francois Venter, Eric Delaporte , Simiso Sokhela, Charles Introduction Thank you for that introduction Scott I also want to thank Concurrences Review and NYU Stern for holding this excellent conference Im pleased to be here delivering my first public remarks Study 1249. Elvitegravir-Cobicistat-TAF-FTC in HIV/HBV Coinfection . Study 1249: . Design. Source: Gallant J, et al. . J. . Acquir. Immune . Defic. . Syndr. . 2016;73:294-8.. Baseline ART. (n = 72). ROCKET II. Switching to TDF-FTC from ABC-3TC . for Hyperlipidemia . ROCKET II. : Study Design. Source: Behrens G, et al. . Antivir. . Ther. . . 2012;17:1011-20.. TDF-FTC + LPV-RTV. (. n = . 42). ABC-3TC + LPV-RTV. Andrew Hill, Francois Venter, Eric . Delaporte. , . Simiso. Sokhela, Charles . Kouanfack. , . Michelle Moorhouse. , Kaitlyn McCann, Bryony Simmons. , . Alexandra . Calmy. Disclosures. Speaker fees and honoraria from Gilead Sciences, AbbVie, Cipla, Johnson and Johnson, Sanofi, Pfizer, ViiV Healthcare, Mylan and Southern African HIV Clinicians Society. RADAR Trial. Raltegravir. + Darunavir/r versus TDF-FTC + Darunavir/r. RADAR: Study Design. Source: . Bedimo. RJ, et al. . PLoS. One. 2014;9:e106221.. Darunavir QD + Ritonavir QD + Raltegravir BID .